Article
Agent delays bone metastases in men with castration-resistant prostate cancer
The RANK ligand inhibitor denosumab (XGEVA) may be able to prevent or at least delay multiple and/or symptomatic bone metastases in men with castration-resistant prostate cancer (CRPC) at high risk of bone metastases.
Related Videos
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Adoption of New Treatment Modalities to Treat BPH
Safety data on Black patients from ARANOTE
Current Unmet Needs in ccRCC Diagnosis
Decision-Making in Small Renal Masses
Related Content
